Sanofi (NASDAQ:SNY) Shares Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. increased its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 6.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,277,394 shares of the company's stock after purchasing an additional 211,641 shares during the period. Envestnet Asset Management Inc. owned 0.13% of Sanofi worth $181,764,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Invesco Ltd. lifted its position in Sanofi by 3.5% in the fourth quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock valued at $581,619,000 after acquiring an additional 408,752 shares during the last quarter. Bank of America Corp DE lifted its position in Sanofi by 3.8% in the fourth quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock valued at $579,587,000 after acquiring an additional 441,637 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after acquiring an additional 5,091,304 shares during the last quarter. Boston Partners lifted its position in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock valued at $260,607,000 after acquiring an additional 2,501,073 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in Sanofi by 10.8% in the fourth quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock valued at $182,164,000 after acquiring an additional 369,530 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Trading Down 0.3%

Shares of Sanofi stock opened at $48.18 on Wednesday. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. The company's 50-day simple moving average is $50.41 and its 200-day simple moving average is $52.09. The firm has a market cap of $118.16 billion, a price-to-earnings ratio of 17.21, a price-to-earnings-growth ratio of 1.05 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same period in the previous year, the business posted $1.78 earnings per share. The business's revenue was down 11.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were given a dividend of $2.0369 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is 57.14%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SNY shares. BNP Paribas started coverage on shares of Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target for the company. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Finally, Morgan Stanley set a $56.00 target price on shares of Sanofi in a report on Monday, June 2nd. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.